Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
#4345 Real-life results of the treatment with lutetium in advanced neuroendocrine tumours
Introduction: Therapy using lutetium-177 dotatate (177LU) was approved in Europe in 2017 for the treatment of advanced neuroendocrine tumours (NETs). Since then, it has become part of the strategies for treating NETs, making it now possible to evaluate real-life results.
Conference:
Presenting Author: Campos Ramírez S
Authors: Campos Ramírez S, Andrés A, Gómez Mugarza P, Blanco Abad C, Monreal Cepero M,
Keywords: Neuroendocrine tumour, Lutetium, Efficacy, Toxicity, Real-Word Evidence,
Introduction: Everolimus 10mg PO daily is approved for patients (pts) with advanced G1/G2 neuroendocrine tumours (NET) but is associated with significant toxicity, including 20% of serious infections in real-world pts. In phase I trials, 5mg/day was sufficient to inhibit the mTOR pathway. Retrospective data suggest that 5mg/day is similarly effective to 10mg/day but less toxic.
Conference:
Presenting Author:
Authors: Riechelmann R, Campos A, Durant L, Bulzico D,
Keywords: everolimus, neuroendocrine tumour, dose optimisation, toxicity,
#2828 G3 Neuroendocrine Tumours and Carcinomas: Clinicopathological Features for Distinct Entities
Introduction: The 2019 WHO subclassified the grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) into neuroendocrine carcinoma (NEC) or tumors (G3 NET). Yet, few data exist on clinical and treatment profiles for G3 NET.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Taboada R
Authors: Taboada R, Claro L, Campos F, Felismino T, de Jesus V,
Keywords: neuroendocrine, high grade, clinicopathological, carcinoma, G3,
#2201 Early Prognostic Factors in Medullary Thyroid Carcinoma
Introduction: Medullary thyroid carcinoma (MTC) prognosis has been related with several variables, being calcitonin doubling time one of the most important prognostic factor. However, it is not evaluable in the early postoperative period.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Muñoz de Nova J, Di Martino M, Marín Campos C, Lahera Vargas M, Mora Guzmán I,
Keywords: medullary thyroid carcinoma, thyroid surgery, prognosis,
#1179 A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results
Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Cives M, Strosberg J, Campos T, Weber T, Nickerson M,
Keywords: axitinib, anti-angiogenesis, VEGFR,